The effect of statin therapy on endothelial function in type 2 diabetes without manifest cardiovascular disease.

OBJECTIVE Cardiovascular disease (CVD) is the most important cause of mortality in patients with type 2 diabetes and is preceded by endothelial dysfunction. Flow-mediated dilation (FMD) is a noninvasive technique for measuring endothelial dysfunction. We aimed to determine the effect of long-term statin therapy versus placebo on FMD in patients with type 2 diabetes without manifest CVD. RESEARCH DESIGN AND METHODS A randomized, placebo-controlled, double-blind trial was performed with 250 type 2 diabetic patients. Patients were given 0.4 mg cerivastatin or placebo daily. In August 2001, when cerivastatin was withdrawn from the market, the 0.4 mg cerivastatin was replaced by 20 mg simvastatin, without deblinding the study. The primary end point was the change in FMD, measured by B-mode ultrasound, after 2 years. RESULTS Determinants of baseline FMD were diabetes duration, common carotid intima-media thickness, and brachial artery diameter. FMD at baseline was 1.51% in the placebo group and 1.66% in the statin group and did not change significantly after 2 years. CONCLUSIONS The 2-year statin therapy had no effect on FMD in type 2 diabetes. Statin-induced improvement of cardiovascular risk in patients with type 2 diabetes may be mediated through mechanisms other than increased nitric oxide availability.

[1]  H. Putter,et al.  Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease. , 2004, Diabetes care.

[2]  J. Ulbrecht,et al.  Biological correlates of day-to-day variation in flow-mediated dilation in individuals with Type 2 diabetes: a study of test–retest reliability , 2004, Diabetologia.

[3]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[4]  A. Iskandrian,et al.  Brachial artery reactivity in asymptomatic patients with type 2 diabetes mellitus and microalbuminuria (from the Detection of Ischemia in Asymptomatic Diabetics-brachial artery reactivity study). , 2004, The American journal of cardiology.

[5]  L. Bouter,et al.  Type 2 diabetes is associated with impaired endothelium-dependent, flow-mediated dilation, but impaired glucose metabolism is not; The Hoorn Study. , 2004, Atherosclerosis.

[6]  Sandeep Vijan,et al.  Pharmacologic Lipid-Lowering Therapy in Type 2 Diabetes Mellitus: Background Paper for the American College of Physicians , 2004, Annals of Internal Medicine.

[7]  T. Marwick,et al.  The relative importance of vascular structure and function in predicting cardiovascular events. , 2004, Journal of the American College of Cardiology.

[8]  L. Khaodhiar,et al.  The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. , 2004, The Journal of clinical endocrinology and metabolism.

[9]  N. Fukuda,et al.  Time course differences for statin-induced pleiotropic effects in hypercholesterolemic patients. , 2003, International journal of cardiology.

[10]  J. Beckman,et al.  Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I , 2013, European heart journal.

[11]  A. Ignaszewski,et al.  The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease. , 2003, Journal of the American College of Cardiology.

[12]  Michael T. Watkins,et al.  Predictive value of noninvasivelydetermined endothelial dysfunction for long-term cardiovascular events inpatients with peripheral vascular disease , 2003 .

[13]  J. Liao,et al.  Endothelium-Dependent Effects of Statins , 2003 .

[14]  F. Logerfo,et al.  The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. , 2003, Metabolism: clinical and experimental.

[15]  A. Ceriello,et al.  Evidence for an Independent and Cumulative Effect of Postprandial Hypertriglyceridemia and Hyperglycemia on Endothelial Dysfunction and Oxidative Stress Generation: Effects of Short- and Long-Term Simvastatin Treatment , 2002, Circulation.

[16]  F. Coppi,et al.  Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. , 2002, Journal of the American College of Cardiology.

[17]  M. Bots,et al.  Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial. , 2002, Diabetes care.

[18]  R. Bucala,et al.  Advanced glycation end products and endothelial dysfunction in type 2 diabetes. , 2002, Diabetes care.

[19]  T. Rabelink,et al.  Intensive Lipid Lowering by Statin Therapy Does Not Improve Vasoreactivity in Patients With Type 2 Diabetes , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[20]  M. Watkins,et al.  Risk Stratification for Postoperative Cardiovascular Events via Noninvasive Assessment of Endothelial Function: A Prospective Study , 2002, Circulation.

[21]  David M. Herrington,et al.  Erratum: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. A report of the international brachial artery reactivity task force (Journal of American College of Cardiology (2002) 39 (257-265)) , 2002 .

[22]  E. Benjamin,et al.  Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. , 2002, Journal of the American College of Cardiology.

[23]  K. Chayama,et al.  Usefulness of flow-mediated dilation of the brachial artery and/or the intima-media thickness of the carotid artery in predicting coronary narrowing in patients suspected of having coronary artery disease. , 2001, The American journal of cardiology.

[24]  M. Huisman,et al.  Impaired endothelium-dependent vasodilation in type 2 diabetes mellitus and the lack of effect of simvastatin. , 2001, Cardiovascular research.

[25]  W. Sheu,et al.  Improvement in endothelial dysfunction with LDL cholesterol level < 80 mg/dl in type 2 diabetic patients. , 2001, Diabetes care.

[26]  K. Egashira,et al.  Cerivastatin, a Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor, Improves Endothelial Function in Elderly Diabetic Patients Within 3 Days , 2001, Circulation.

[27]  K. Kostner,et al.  Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. , 2000, The American journal of cardiology.

[28]  S. Jacob,et al.  Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. , 2000, Circulation.

[29]  C. Meisner,et al.  Noninvasive determination of endothelium-mediated vasodilation as a screening test for coronary artery disease: pilot study to assess the predictive value in comparison with angina pectoris, exercise electrocardiography, and myocardial perfusion imaging. , 1999, American heart journal.

[30]  K. Tan,et al.  Influence of low density lipoprotein (LDL) subfraction profile and LDL oxidation on endothelium-dependent and independent vasodilation in patients with type 2 diabetes. , 1999, The Journal of clinical endocrinology and metabolism.

[31]  W. Sheu,et al.  Endothelial dysfunction is not reversed by simvastatin treatment in type 2 diabetic patients with hypercholesterolemia. , 1999, Diabetes care.

[32]  K. Kugiyama,et al.  Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. , 1999, Journal of the American College of Cardiology.

[33]  U. Laufs,et al.  Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. , 1998, Circulation.

[34]  M W Ramsey,et al.  Endothelium and inelastic arteries: an early marker of vascular dysfunction in non-insulin dependent diabetes , 1996, BMJ.

[35]  A. Yeung,et al.  Close relation of endothelial function in the human coronary and peripheral circulations. , 1995, Journal of the American College of Cardiology.

[36]  W E Haefeli,et al.  Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. , 1995, Circulation.

[37]  N. Fineberg,et al.  Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. , 1994, The Journal of clinical investigation.

[38]  J. Neaton,et al.  Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial , 1993, Diabetes Care.

[39]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[40]  M. Watkins,et al.  Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. , 2003, Journal of the American College of Cardiology.

[41]  M. Hecker,et al.  Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[42]  R. Caldwell,et al.  Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. , 1999, Journal of the American College of Cardiology.

[43]  A. Baron,et al.  Vascular reactivity. , 1999, The American journal of cardiology.

[44]  G. Plotnick,et al.  Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. , 1996, The American journal of cardiology.